Vanguard Capital Management
XGN icon

Vanguard Capital Management’s Exagen XGN Stock Holding History

Vanguard Capital Management’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85M Sell
612,832
-65,820
-10% -$248K ﹤0.01% 3305
2026
Q1 		$2.04M Buy
+678,652
New +$2.62M ﹤0.01% 3357

Other funds holding XGN

NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Vanguard Capital Management's XGN Position: Q2 2026 in Review

Vanguard Capital Management reduced its Exagen (XGN) stake by 9.7% in Q2 2026, selling an estimated $248K and leaving 612,832 shares worth $2.85M. The position accounts for ﹤0.01% of the portfolio, ranked #3305.

Vanguard Capital Management first reported a position in XGN in Q1 2026 and has held it in 2 quarters since. 53 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • Vanguard Capital Management held 612,832 shares of Exagen worth $2.85M as of Q2 2026.
  • Vanguard Capital Management sold 65,820 Exagen shares in Q2 2026, an estimated $248K.
  • Exagen made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3305 holding.
  • Vanguard Capital Management first reported a position in Exagen in Q1 2026 and has held it in 2 quarters since.
  • 53 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.